www.theAIRnet.org

Tag Archives | Pharmaceutical Industry

How Big Pharma was captured by the one percent

By Alexander Zaitchik (originally published by New Republic) - Donald Trump’s plan to lower prescription drug prices, announced May 11 in the Rose Garden, is a wonky departure for the president. In his approach to other signature campaign pledges, Trump has selected blunt-force tools: concrete walls, trade wars, ICE raids… [Cross-posted from New Republic publication of June 28, 2018 at https://newrepublic.com/article/149438/big-pharma-captured-one-percent]

Continue Reading 0

INET grantee Lazonick’s research shapes DC share buyback debate

By Institute Staff (originally published by Institute for New Economic Thinking (INET) Perspectives) – INET grantee William Lazonick has conducted extensive research on share buybacks, which was recently featured in letters sent by Sen. Tammy Baldwin (D-WI) to Securities and Exchange Commission nominees Robert J. Jackson, Jr. and Hester Pierce, and in written questions Senator Baldwin submitted to Lori […]

Continue Reading 0

We get sick, they get rich

By Sam Pizzigati (originally published by Fairborn Daily Herald) - Our current health care system in the United States works just fine — for the corporate executives who run it… [Cross-posted from Fairborn Daily Herald publication of October 18, 2017 at http://www.fairborndailyherald.com/opinion/21348/we-get-sick-they-get-rich]

Continue Reading 0

Farmaci e soldi: le versione di William,

By Michele Bocci (originally published by La Repubblica) - POCHI INVESTIMENTI in ricerca e sviluppo e troppe operazioni finanziarie: emblematico il frequente ricorso al buyback, che consiste nell’acquisto a fini speculativi delle azioni dell’azienda stessa da parte dei suoi top manager… [Cross-posted from La Repubblica publication of October 17, 2017 at http://ricerca.repubblica.it/repubblica/archivio/repubblica/2017/10/17/farmaci-e-soldi-la-versione-di-william29.html]

Continue Reading 0

Big Pharma plays every dirty trick in the book to transform teens and adults into opioid-zombiefied addicts,

By Lynn Stuart Parramore (originally published by AlterNet) - Over a 40-year career, Philadelphia attorney Daniel Berger has obtained millions in settlements for investors and consumers hurt by a rogues’ gallery of corporate wrongdoers from Exxon to R.J. Reynolds Tobacco. But when it comes to what America’s prescription drug makers have done to drive one of the […]

Continue Reading 0

Meet the CEO who says that excessive CEO pay is thrashing America—and hurting investors

By Arne Alsin (originally published by Forbes) - As a general rule, you probably won’t find too many CEOs that are particularly critical of high pay. Don’t bite from the hand that feeds you, right?.. [Cross-posted from Forbes publication of September 28, 2017 at https://www.forbes.com/sites/aalsin/2017/09/28/meet-the-ceo-who-says-excessive-ceo-pay-is-trashing-america/#2e623afd168c]

Continue Reading 0

It looks like Trump’s people have fallen for big pharma’s nonsense, hook, line, and sinker

By Linette Lopez (originally published by Business Insider) - The Trump administration has yet to take any meaningful action on lowering the price of drugs in America, and we may have just found out why. In a CNBC interview on Friday, Commerce Secretary Wilbur Ross demonstrated that he had fallen for big pharma’s nonsense hook, line, and sinker… [Cross-posted from […]

Continue Reading 0

We get sick, they get rich

By Sam Pizzigati (originally published by Inequality.org) – Our current health care system in the United States works just fine — for the corporate executives who run it. Take, for instance, Michael Mussallem… [Cross-posted from Inequality.org publication of September 20, 2017 at https://inequality.org/great-divide/get-sick-get-rich/]

Continue Reading 0

Les pharmas dépensent autant pour leurs actionnaires que pour la recherché

By Marie Maurisse (originally published by Le Temps) - Entre 2006 et 2015, Novartis a versé presque autant d’argent à ses actionnaires qu’elle n’en a investi en recherche et développement (R&D). Une étude récente pointe les dérives d’une telle évolution… [Cross-posted from Le Temps publication of August 18, 2017 at https://www.letemps.ch/economie/pharmas-depensent-autant-leurs-actionnaires-recherche?utm_campaign=article&utm_medium=share&utm_source=facebook]

Continue Reading 0

developed by bodhiWeb